Audentes Therapeutics (BOLD) Rating Lowered to Buy at ValuEngine
Several other brokerages also recently commented on BOLD. Wedbush raised their target price on Audentes Therapeutics from $52.00 to $57.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 9th. Zacks Investment Research downgraded Audentes Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, March 12th. Cowen restated a “buy” rating on shares of Audentes Therapeutics in a research note on Thursday, January 31st. Guggenheim upgraded Audentes Therapeutics from a “neutral” rating to a “buy” rating and set a $35.00 target price for the company in a research note on Friday, January 11th. Finally, Mizuho restated a “buy” rating and issued a $45.00 target price on shares of Audentes Therapeutics in a research note on Friday, February 1st. One analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. Audentes Therapeutics presently has an average rating of “Buy” and a consensus price target of $37.08.
NASDAQ BOLD traded up $0.12 during trading hours on Monday, hitting $40.44. The company had a trading volume of 225,917 shares, compared to its average volume of 514,327. Audentes Therapeutics has a 52 week low of $17.95 and a 52 week high of $46.18. The company has a market cap of $1.72 billion, a P/E ratio of -11.89 and a beta of 1.96.
In other Audentes Therapeutics news, VP Suyash Prasad sold 10,000 shares of the firm’s stock in a transaction dated Monday, February 25th. The stock was sold at an average price of $30.06, for a total value of $300,600.00. Following the sale, the vice president now owns 28,236 shares of the company’s stock, valued at approximately $848,774.16. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Louis G. Lange sold 20,000 shares of the firm’s stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $36.00, for a total value of $720,000.00. Following the completion of the sale, the director now directly owns 306,099 shares in the company, valued at approximately $11,019,564. The disclosure for this sale can be found here. In the last ninety days, insiders sold 51,000 shares of company stock worth $1,650,600. Insiders own 6.60% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp increased its position in shares of Audentes Therapeutics by 32.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 127,693 shares of the biotechnology company’s stock worth $4,879,000 after purchasing an additional 31,048 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Audentes Therapeutics by 2.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 117,284 shares of the biotechnology company’s stock worth $4,644,000 after purchasing an additional 3,331 shares during the last quarter. BlackRock Inc. boosted its holdings in shares of Audentes Therapeutics by 4.5% in the 3rd quarter. BlackRock Inc. now owns 2,567,986 shares of the biotechnology company’s stock valued at $101,667,000 after buying an additional 109,815 shares during the period. Dimensional Fund Advisors LP acquired a new position in shares of Audentes Therapeutics in the 3rd quarter valued at about $6,708,000. Finally, Allianz Asset Management GmbH boosted its holdings in shares of Audentes Therapeutics by 7.4% in the 3rd quarter. Allianz Asset Management GmbH now owns 74,841 shares of the biotechnology company’s stock valued at $2,963,000 after buying an additional 5,168 shares during the period.
About Audentes Therapeutics
Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.
Featured Article: NASDAQ
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.